Anti-hypertensive and pleiotropic effects of phyllanthus emblica extract as an add-on therapy in patients with essential hypertension- A randomized double blind placebo controlled trial

JIPMER Puducherry0 个研究点目标入组 150 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•Patients with essential hypertension aged >= 18 years, irrespective of gender, who meet any one of the following criteria
•1.Newly diagnosed and started on amlodipine 5 mg or enalapril 5 mg
•2.Already on treatment with stable dose of amlodipine 5 mg or enalapril 5 mg for atleast 1 month and has not yet attained target blood pressure goals (130 mmHg of systolic and 80 mmHg of diastolic blood pressure) and not requiring dose escalation or addition of second anti-hypertensive agent according to clinical judgment of the treating physician

•1. Patients with secondary hypertension
•2. Patients with systolic BP >160 mmHg and diastolic BP >100 mmHg
•3. Patients with hypertensive urgency/ emergency
•4. Patients receiving antihypertensive drugs other than amlodipine and enalapril
•5. Patients not on stable dose of oral hypoglycemic drugs and/or insulin for past 1 month
•6. Pregnant and lactating women, women in reproductive age group not practicing contraceptive measures
•7. Patients with hepatic impairment (elevated liver enzymes > 2 times upper normal limit)
•8. Patients with renal impairment (S.Creatinine > 1.2 mg/dL)
•9. Patients with history of coronary artery disease and peripheral vascular disease
•10. Patients who had participated in other trials in the past three months.
•11. Patients on herbal medications
•12. Patients not willing to sign written informed consent

发起方